Journal article
Comparative efficacy of switching to natalizumab in active multiple sclerosis
T Spelman, T Kalincik, A Zhang, F Pellegrini, H Wiendl, L Kappos, L Tsvetkova, S Belachew, R Hyde, F Verheul, F Grand-Maison, G Izquierdo, P Grammond, P Duquette, A Lugaresi, J Lechner-Scott, C Oreja-Guevara, R Hupperts, T Petersen, M Barnett Show all
Annals of Clinical and Translational Neurology | WILEY | Published : 2015
DOI: 10.1002/ACN3.180
Abstract
Objective: To compare treatment efficacy and persistence in patients who switched to natalizumab versus those who switched between glatiramer acetate (GA) and interferon-beta (IFNb) after an on-treatment relapse on IFNb or GA using propensity score matched real-world datasets. Methods: Patients included were registered in MSBase or the TYSABRI Observational Program (TOP), had relapsed on IFNb or GA within 12 months prior to switching to another ther-apy, and had initiated natalizumab or IFNb/GA treatment ≤6 months after discontinuing prior therapy. Covariates were balanced across post switch treatment groups by propensity score matching at treatment initiation. Relapse, per-sistence, and dis..
View full abstractRelated Projects (2)
Grants
Awarded by National Science Foundation